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ABSTRACT – The growing interest in cannabidiol (CBD), specifically a
pure form of CBD, as a treatment for epilepsy, among other conditions,
is reflected in recent changes in legislation in some countries. Although
there has been much speculation about the therapeutic value of cannabis-
based products as an anti-seizure treatment for some time, it is only within
the last two years that Class I evidence has been available for a pure form of
CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut
syndrome and Dravet syndrome. However, just as we are beginning to
understand the significance of CBD as a treatment for epilepsy, in recent
years, abroad spectrumofproducts advertised to containCBDhasemerged
on the market. The effects of these products are fundamentally dependent
on the purity, preparation, and concentration of CBD and other compo-
nents, and consensus and standardisation are severely lacking regarding
their preparation, composition, usage and effectiveness. This review aims
to provide information to neurologists and epileptologists on the therapeu-
tic value of CBD products, principally a purified form, in routine practice
for patients with intractable epilepsy.
Key words: epilepsy, cannabis, cannabidiol, CBD, oil, guidelines, Dravet,
Lennox-Gastaut, Epidiolex, Epidyolex
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he therapeutic potential of cannabis-related prod-
cts has been suggested for many years (Perucca,
017), and interest in the subject in recent decades
as fluctuated in parallel with perceptions of cannabis
nd changes in legislation. With the realisation
hat (-)-trans--9-tetrahydrocannabinol (THC) is a
omponent with prominent psychoactive properties,
ttention shifted to the potential therapeutic value
f cannabidiol (CBD). In recent decades, interest in
he therapeutic value of CBD-containing products,
s anti-inflammatory, anti-emetic, anti-psychotic, and
nti-epileptic treatments, has emerged for a wide
ange of conditions. However, the supporting data
s principally based on anecdotal or in vitro exper-
ments with supraphysiological concentrations. In
ddition, other compounds that may be present in
rtisanal CBD preparations may have independent
hysiological effects, leading to inevitable confu-
ion regarding the effectiveness and safety of the
reparations.
t is only within the last two years that Class I evidence
as become available for a pure form of CBD, based
n placebo-controlled RCTs. In the light of this recent
vidence, this review aims to provide information on
he current status of what is known about CBD as a
herapeutic option for epilepsy, which will likely be of
alue to neurologists and epileptologists. This paper
ontributes to the following competencies of the ILAE
urriculum (Blümcke et al., 2019): “Demonstrate up-
o-date knowledge about the rangeof pharmacological
reatments for epilepsy ; Recommend appropriate ther-
py based on epilepsy presentation ; Demonstrate
p-to-date knowledge about special aspects of phar-
acological treatment ”.
egislation
aws regarding the use of raw herbal cannabis,
annabis extracts and cannabinoid-based medicines
iffer between countries (Abuhasira et al., 2018;
pecchio et al., 2020). Recreational use of cannabis
as been legalised in Canada and Uruguay, as well
s 11 states and the District of Columbia in the US.
ore restricted recreational use has been adopted
n Georgia, South Africa, Spain, and The Netherlands.
he use of herbal cannabis for medicinal purposes is
ow authorised in a number of countries, including
rgentina, Australia, Canada, Chile, Colombia, Croa-
ia, Ecuador, Cyprus, Germany, Greece, Israel, Italy,
amaica, Lithuania, Luxembourg, North Macedonia,
orway, the Netherlands, New Zealand, Peru, Poland,
witzerland, andThailand, aswell as a numberof states
n the US.
annabis and cannabis extracts have not been
pproved by the FDA or the European Medicines
a
t
p
w
s
t
dgency (EMA), although cannabinoid-based products
ave been approved by the FDA as well as by 23
uropean countries andCanada. In some cases, autho-
isation is specific to certain indications, while in
thers the choice of indication may be dictated by the
hysician (Abuhasira et al., 2018).
n the European Union, CBD, in contrast to THC, is not
controlled substance and according to EU law, CBD
roducts must not contain more than 0.2% THC. Sev-
ral companies within the EU produce and distribute
BD-based products obtained from inflorescences
f industrial hemp varieties. No analytical controls
re mandatory and no legal protection or guarantees
egarding the composition and quality is required. An
bligatory testing and basic regulatory framework to
etermine the indication area, daily dosage, route of
dministration, maximum recommended daily dose,
ackaging, shelf life, and stability is also not required.
uch of the ongoing confusion results from whether
uch products should be regulated as a food, a supple-
ent, or medicine.
t is beyond the scope of this review to provide details
or individual countries. However, physicians consid-
ring prescribing cannabis related products should be
ully aware of the relevant legislation in relation to
he heath care service for their specific geographical
ocation. Since the situation can be complex, provi-
ion and use of guidelines from recognised national
rofessional associations and or governmental bod-
es can be extremely helpful. For example, in the UK,
uch guidelines have been provided by the British
aediatric Neurology Association (BPNA, 2018) and
he National Institute for Health and Care Excellence
NICE, 2019). In both, to prescribe a cannabis related
roduct for medicinal use for epilepsy, the prescriber
ust be on the Specialist Register (Reference: Sec-
ion 34D of the Medical Act 1983) and the prescription
houldbemadebya consultant paediatric neurologist.
ithin the UK, responsibility for the prescribing and
otential adverse effects of a cannabis related product
emain with the prescribing clinician. Thus, clinicians
re advised tobeawareof theGeneralMedicalCouncil
GMC) guidance on prescribing unlicensed medica-
ion (GMC, 2019), and to investigate whether medical
rotection insurance andhospital indemnitywill cover
hem for prescription of unlicensed cannabis related
roducts. Should a doctor feel under pressure to pre-
cribe a medication that they believe is not in the
atient’s interests, thenparagraph5dof theGMCguid-Epileptic Disord, Vol. 22, No. 1, February 2020
nce “Consent: patients and doctorsmaking decisions
ogether” is relevant (GMC, 2008). It states: “If the
atient asks for a treatment that the doctor considers
ould not be of overall benefit to them, the doctor
hould discuss the issues with the patient and explore
he reasons for their request. If, after discussion, the
octor still considers that the treatment would not be
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5f overall benefit to the patient, they do not have to
rovide the treatment. But they should explain their
easons to the patient, and explain any other options
hat areavailable, including theoption toseekasecond
pinion”.
rtisanal products advertised with CBD
ontent
he known physiologically active components of
annabis include cannabinoids, terpenoids, and
avonoids. Plant or phyto cannabinoids are unique to
he cannabis plant. Over a hundred different cannabi-
oidcompoundshavebeen isolated fromthecannabis
lant, for which various chemovars exist (Cannabis
ndica, ruderalis, and particularly sativa being the
ost common). Of these compounds, only 16 exist in
eaningful concentrations; these include THC, CBD,
annabichromene (CBC), and cannabigerol (CBG) (as
oth acid and varin forms). The majority of animal and
n vitro studies have focussed on THC and CBD, and
hereas the effect of THC is less clear and appears to
xhibit both proconvulsant and anticonvulsant prop-
rties under different conditions, CBD demonstrates
lear anti-convulsant properties, making it a focus as a
otential treatment for epilepsy.
n abundance of CBD-related products is currently
ommercially available, ranging extensively in purity,
ontent of effective compounds and price. The global
arket for these products is considerable and accord-
ng to the Centre for Medicinal Cannabis (2019) in the
K, at the current rate, the market will be worth one
illion pounds/year in 2025.
mportantly, the content of CBD-related products is
ependent on the type of cannabis plant as well as the
ifferent parts of the plant and growing conditions.
emp and marijuana may be considered as different
arieties of the same cannabis plant; whereas hemp is
ow in all cannabinoids including THC (≤0.3%), mari-
uana has a higher THC content (>0.3%).
emp seed oils (from seeds) containminimal cannabi-
oids (i.e. THC); this depends principally on the extent
fwashingprior to subsequentprocessing, as cannabi-
oids in the flowers and leaves appear to transfer to
he outer coating or husk of the seed during harvest-
ng and preparation. Cannabis oils (from flowers and
eaves ofmarijuana) contain variable levels of CBD and
HC, depending on the chemovars. CBD-enriched oilspileptic Disord, Vol. 22, No. 1, February 2020
from flowers and leaves of hemp) contain high levels
f CBD and some THC. The maximum ratio of CBD to
HC that can be achieved without subsequent purifi-
ation, irrespective of the chemovar, is 20:1, however, it
hould be noted that THC is significantly more potent
50-100-fold) than CBD. Moreover, for CBD-enriched
ils advertised as “high CBD/low THC” content, in
P
W
m
cEpilepsy and cannabidiol
rder to obtain CBD at similar doses to those used in
andomisedcontrolled trials (seebelow), themeaning-
ul amount of THC may be higher than expected. For
child of 18 kg taking 300 mg CBD/day, this equates
o 15 mg THC/day, based on a 20:1 CBD:THC ratio in
reparations, which is similar to the maximum daily
osage of marinol or dronabinol, a synthetic -9-THC
prescribed for chemotherapy-induced nausea and
omiting as well as weight loss in cancer or AIDS/HIV
atients).
alenic products are available in the form of
annabis decoction filter bags and cannabis extracts as
ils, creams, and supplement capsules. Supplements
ppear to be the most common form, often referred
o as “CBD dietary supplements” or “CBD-enriched
ils”, obtained from extraction of different Cannabis
ativa L. chemovars with high CBD content. Of the
BD-enriched oils, there are six main varieties avail-
ble on the market in Europe: Bedrocan, Bedrobinol,
ediol, Bedica, Bedrolite and Bedropuur (table 1).
t is important to emphasise that these products
emonstrate significant variation with regards to
ontent, which is dependent not only on the initial
ource of the plant (e.g. the use of fertilisers and
esticides) but also the method by which they are
repared (Carcieri et al., 2018; Pegoraro et al., 2019;
ettiol et al., 2019). There are a number of different
ethods to prepare suchoils, themost commonbeing
supercritical CO2 extraction”. This leads to an extract
ich in lipophilic cannabis components plus waxes,
owever, different biologically active compounds can
e isolated during subsequent procedures, includ-
ng omega-3 fatty acids, vitamins, terpenes, flavonoids,
nd other phytocannabinoids such as CBC, CBG,
annabidivarin (CBDV), and cannabinol (CBN) as a
egradant (according to how the fresh thematerials is)
Calviet al., 2018). Terpenes represent the largest group
with more than 100 different molecules) of cannabis
hytochemicals; these caneasily cross cellmembranes
nd the blood-brain barrier. Moreover, a synergistic
ffect between cannabinoids and terpenes has been
ypothesised, but not proven (Russo, 2011; Aizpurua-
laizola et al., 2016; Santiago et al., 2019).
t is also worth mentioning that an adequate dose of
BD based on commercially available CBD-enriched
ils (up to 10-20 mg/kg/day), similar to doses used in
andomised controlled trials (see below), comes at
onsiderable financial cost to the family; in excess of
00 euros per month.3
roduct labelling
hen it comes to CBD-enriched oils, there are
ajor concerns regarding THC, CBD and terpene
oncentration, as well as appropriate preparation
Journal Identification = EPD Article Identification = 1141 Date: February 17, 2020 Time: 4:55 pm
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Table 1. THC and CBD content of CBD-enriched oils and purified CBD preparations.
Product THC content CBD content
CBD-enriched oils
Bedrocan 22% <1%
Bedrobinol 13.5% <1%
Bediol 6.5% 8%
Bedica 14% <1%
Bedrolite 0.4% 9%
Bedropuur <1%
FM1
FM2
Pedanios 22/1 22% <1
Pedanios 8 8% 8
Pedanois 1/8 <1% 8
9%
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GW Pharmaceuticals plc
Sativex (GW)
Epidiolex (GW)
ethods and storage conditions. These may vary sig-
ificantly (Carcieri et al., 2018; Pavlovic et al., 2018),
eading to insufficient quality control. Moreover, lab-
ratory analyses have shown that the cannabinoid
ontent is often not reflected on the marketing label
Vandrey et al., 2015).
ased on a report by the Centre for Medicinal
annabis (2019) in the UK, there is an urgent need
or a move towards accurate labelling regarding CBD
ontent, as many products are sold with quantities
f CBD which are well below those used in clinical
rials. In the study by Bonn-Miller et al. (2017), the
abel accuracy of 84 products was analysed. Overall,
BD concentration ranged from 0.10 to 655.27 mg/mL
median: 9.45 mg/mL; median labelled concentration:
5.00 mg/mL). Of the products tested, 42.85% (n = 36)
roducts were under-labelled, 26.19% (n = 22) were
ver-labelled, and 30.95% (n = 26) were accurately
abelled. The level of CBD in the over-labelled prod-
cts in the study is similar in magnitude to levels that
riggeredawarning fromtheUSFoodandDrugAdmin-
stration (FDA) to 14 businesses in 2015-2016, indicating
hat there is a continued need for federal and state
egulatory agencies to take steps to ensure accurate
abelling of these consumer products.
D
c
o
(
w
(
g99%
51% 49%
>98%
nder-labelling is of less concern, as CBD itself does
ot appear to be susceptible to abuse and there have
een no reported serious adverse effects (AEs) at high
oses, however, the THC content observed may be
ufficient toproduce intoxicationor impairment, espe-
ially among children. Clear labelling regarding the
xact concentration of CBD is not yet mandatory, and
here is clearly a need to introduce stricter legislation
egarding accurate content labelling.
ffectiveness as a treatment for epilepsy
necdotal reports have fuelled public interest and,
nderstandably, have inspired families to seek CBD-
elated products for the treatment of drug-resistant
pilepsy (Filloux, 2015). The most well-known report
s that of Charlotte, a five-year-old girl in the US
ho was diagnosed in 2013 with SCN1A-confirmedEpileptic Disord, Vol. 22, No. 1, February 2020
ravet syndrome, with up to 50 generalised tonic-
lonic seizures per day. Following three months
f treatment with high-CBD-strain cannabis extract
later marketed as “Charlotte’s Web”), her seizures
ere reported to have reduced by more than 90%
Maa and Figi, 2014). Other anecdotal reports sug-
esting that CBD may improve seizure control as
Journal Identification = EPD Article Identification = 1141 Date: February 17, 2020 Time: 4:55 pm
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well as alertness, mood and sleep have also been
ocumented (Porter and Jacobson, 2013;Hussain et al.,
015; Schonhofen et al., 2018).
number of studies have investigated the effect of
ral cannabis extracts on intractable epilepsy, based
nparental reporting. These include the studybyPress
t al. (2015) of 75 patients (23% with Dravet syndrome
nd89%with Lennox-Gastaut syndrome) in theUS and
zadok et al. (2016) of 74 patients in Israel over an aver-
ge of sixmonths; 50% seizure reductionwas reported
n 33%, and 50-75% seizure reduction in 34% in the two
tudies, respectively. In a retrospective studybyPorcari
t al. (2018) of 108 children with epilepsy in the US,
he addition of CBD oil over an average of six months
esulted in >50% seizure reduction in 29% patients,
ith 10% becoming seizure-free.
ased on a meta-analysis (n=670), Pamplona et al.
2018) provide evidence in support of the therapeu-
ic value of high-content CBD treatments (CBD-rich
annabis extract or purified CBD). The results indi-
ated a favourable effect for both patients with
BD-rich extracts (6.1 mg/kg/day CBD) and purified
BD (27.1 mg/kg/day), which was in fact more pro-
ounced in patients taking the CBD-rich extracts. This
ay provide evidence in favour of the inclusion of
ther components within CBD-rich extracts offering
eneficial entourage effects.
verall, the studies on CBD-enriched oils indicate a
0% reduction in seizures in roughly 30-40% patients.
owever, it should be emphasised that these are
ncontrolled studies with heterogeneous CBD prepa-
ations, the CBD content of which varied significantly
estimated at <0.02-50 mg/kg/day). In the study of
ress et al. (2015), the effect of cannabis extracts was
nvestigated in a cohort of paediatric patients with
pilepsy in a single tertiary epilepsy centre in Col-
rado, where the law on cannabis-related products
s more relaxed. Interestingly, the overall responder
ate (47%) for patients who had moved to Colorado
or treatment was greater than that (22%) of those who
ere already living in Colorado, indicating a possible
ositive reporting bias and the need for appropriately
ontrolled studies.
dverse events
he studies described above reported AEs in 40-
0% patients, including increased seizure frequency,pileptic Disord, Vol. 22, No. 1, February 2020
astrointestinal disturbances/diarrhoea, appetite alter-
tion, weight changes, nausea, liver dysfunction,
ancreatitis and, particularly, somnolence and fatigue.
ore serious effects included developmental regres-
ion, abnormal movements and status epilepticus.
ore long-term effects regarding cannabis-derived
roducts have generally been gathered based on
i
t
v
e
b
c
bEpilepsy and cannabidiol
ndirect evidence, however, no hard conclusions can
e drawn, mainly due to methodological limitations
dosage of THC and other cannabis-derived products,
uration of exposure, concordant addiction to other
rugs, genetic factors, psychiatric comorbidity, etc.).
ong-term data from studies on prenatal and adoles-
ent exposure to cannabis products indicate, however,
possible negative and lasting effect on cognitive and,
articularly, behavioural functions (Lagae, 2020).More-
ver, the externalisation of behavioural problems and
decrease in IQ have been reported as a result of
hronic cannabis use. Clearly, long-term studies using
arge childhood epilepsy cohorts are needed on the
hronic use of CBD and cannabis-related products.
urified CBD (Epidiolex/Epidyolex®)
purified preparation of CBD is available from
W Pharmaceuticals plc, under the name of
pidiolex/Epidyolex® (>98% CBD). Interest has
o far largely focussed on Epidiolex as an add-on drug
or cases of epilepsy. Another product, Sativex® (also
nown as Nabiximol) (51% THC, 49% CBD), made
y the same company as a refined extract, has been
pproved for cases of neuropathic pain, spasticity,
veractive bladder and other symptoms of multiple
clerosis in some countries.
urified CBD has been shown to demonstrate posi-
ive effects against a wide spectrum of seizures and
pilepsy based on animal models (Rosenburg et al.,
017a). While the precise mechanism of action of
BD in the control of epileptic seizures in humans
emains unknown, recent evidence suggests a role
n modulating intracellular Ca2+ (including effects on
euronal Ca2+ mobilisation via GPR55 and TRPV1) and
odulating adenosine-mediated signalling (Gray and
halley, 2020).
n 2017 and 2018, the first randomised controlled
rials for pharmaceutically prepared Epidiolex were
ublished for Dravet syndrome and Lennox-Gastaut
yndrome, respectively (Devinsky et al., 2017; Thiele et
l., 2018), and in June 2018, the FDA approved CBD as
n add-on antiepileptic drug for patients with Lennox-
astaut syndrome or Dravet syndrome over the age
f two. Epidiolex was also later approved by the EMA
n September 2019 for patients over two years of age
ith Dravet syndrome and Lennox-Gastaut syndrome,5
n conjunction with clobazam. However, accessibility
o Epidiolex outside of Europe and the US remains
ariable (e.g. only patients involved in RCTs may be
ligible), due to a lack of approval and legal reform
y central agencies. While such reform is clearly wel-
omed, it cannot come fast enough for those who may
enefit.
Journal Identification = EPD Article Identification = 1141 Date: February 17, 2020 Time: 4:55 pm
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Table 2. Possible AED/CBD interactions.
Enzyme inducer
(↓)
Enzyme inhibitor
(↑)
CBD as an enzyme
inhibitor (↑)
Carbamazepine
Phenytoin
Valproate*
Stiripentol
Felbamate
Clobazam**
Topiramate
Rufinamide
Zonisamide
Eslicarbamazepine
*
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were administered CBD at 20 mg/kg/day (GWPCARE4;Perampanel
Lamotrigine?
Associated with a significant risk of elevated transami-
ases. **Associated with a significant risk of elevated N-
esmethylclobazam, which may cause e.g. sedation.
harmacology and drug interactions
s a therapeutic drug, the pharmacokinetic profile
f CBD exhibits low bioavailability, significant protein
inding (99% protein binding capability), and inter-
ctions with various metabolic pathways in the liver,
ncluding CYPs that are susceptible to pharmacoge-
etic variability and drug interactions. However, as
BD interacts with many enzymes, it is cleared quickly
nd is therefore less susceptible to modulation by
rugs that affect metabolising enzymes. Moreover,
he pharmacokinetic profile of CBD seems relatively
naffected by inhibitors and inducers or genetic back-
round. The bioavailability of oral oil formulations is
imited (<6%) due to extensive first pass metabolism
n the liver (Bialer et al., 2017, 2018).
BD may exhibit numerous interactions with
EDs (Johannessen Landmark and Patsalos, 2010;
ohannessen and Johannessen Landmark, 2010;
ohannessen Landmark et al., 2012, 2016; Patsalos,
013a, 2013b) including both potent enzyme inducers
such as carbamazepine and phenytoin) and inhibitors
such as stiripentol, felbamate and valproate) (table 2),
owever, the clinical significance of these interactions
ay not be meaningful. The most obvious and clin-
cally significant interaction between CBD and other
oncomitantly used drugs, based on clinical trials,
s that with clobazam. CBD, via enzyme inhibition
CYP2C19), may lead to an increase (up to five-fold)
n its less potent metabolite, N-desmethylclobazam
Geffrey et al., 2015; Devinsky et al., 2018a), leading to
oxicity (principally manifesting as sedation [Gaston
t al., 2017]), which may occur at even low levels
1 mg/kg/day) (unpublished observations; Johan-
essen Landmark). In addition, concurrent clobazam
ay lead to increased 7-hydroxy-cannabidiol (an
ctive metabolite of CBD) (Morrison et al., 2019),
hich arguably may lead to better seizure control
y boosting the effect of CBD, however, studies with
nd without clobazam are needed to confirm this.
T
D
(
a
a
lther AEDs with a similarly increased effect, conco-
itant with CBD, may include topiramate, rufinamide,
onisamide and eslicarbazepine (Gaston et al., 2017;
ranco and Perucca, 2019). There are therefore still
number of unanswered questions regarding the
harmacology of CBD (Johannessen Landmark and
randl, 2020; Brodie and Ben-Menachem, 2018).
he clinical impact of such interactions in the indi-
idual patient is difficult to predict. Patients should
e systematically questioned about efficacy, tolerabil-
ty and adherence, and serum concentrations should
e measured if possible and dosages adjusted accord-
ngly to optimise each patient’s treatment.
fficacy as a treatment for epilepsy
he first trials for purified CBD (Epidiolex) were
aunched as an expanded access programme in
014 for patients with significant medically refractory
pilepsy in the form of an open-label, non-controlled
rial for compassionate use (Devinsky et al., 2016).
atients (n=214) with intractable seizures (at least
our weekly) were monitored over a 12-week period
relative to a four-week baseline) with initial CBD
oses of 2.5-5 mg/kg/day, increasing weekly to 25 or
0 mg/kg/day. Overall, a 36.5% median reduction of
otor seizures was reported (49.8% for Dravet syn-
rome patients), and five patients were free of all
otor seizures (of the patients with motor and atonic
eizures, 39% and 56% showed a >50% reduction of
eizures, respectively). This programme was contin-
ed and interim data on >600 patients over a 96-week
eriod were published in 2018 by Szaflarski et al.,
evealing a reduction of median monthly convulsive
eizures by 51% (52% with ≥50% seizure reduction)
nd total seizures by 48% at 12 weeks, with similar
esults over the 96-week period.
ith these very encouraging results, shortly after
he initial launch of this programme, controlled tri-
ls for Epidiolexwere established forDravet syndrome
Devinsky et al., 2017) and Lennox-Gastaut syndrome
Thiele et al., 2018; Devinsky et al., 2018b). For further
etails regarding these trials, refer to Nabbout and
hiele (2020).
ennox Gastaut syndrome
n the two Lennox-Gastaut syndrome double-blind
lacebo-controlled trials, patients (n=171 and 225)Epileptic Disord, Vol. 22, No. 1, February 2020
hiele et al., 2018) or 10 or 20 mg/kg/day (GWPCARE3;
evinskyet al., 2018b) over a 14-week treatment period
including a titration phase of two weeks starting with
dose of 2.5 mg/kg/day, titrated to 10 or 20 mg/kg/day),
nd data were compared relative to a four-week base-
ine observation period. CBD in an oral solution or
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igure 1. Medianpercent reductionof Lennox-Gastaut syndrome
rials (Thiele et al., 2018; Devinsky et al., 2018b) (A), and the open
lacebo was administered as add-on to current AEDs.
orCBDat20mg/kg/day, themedianpercentage reduc-
ion in total seizure frequency was 41% (vs 13.7%
lacebo) and 38.4% (vs 18.5% placebo), and monthlypileptic Disord, Vol. 22, No. 1, February 2020
edian decrease in drop seizures was reported to
e 44% (vs 22% placebo) and 42% (vs 17% placebo)
n the two trials, respectively. At 10 mg/kg/day, the
edian percentage reduction in total seizure fre-
uency was similar at 36.4% (vs 18.5% placebo), and
onthly median decrease in drop seizures was 37%
vs 17% placebo).
m
4
q
B
I
r
pTotal seizures
seizures andmonthly drop seizuresbasedon the twocontrolled
l extension study (Thiele et al., 2019a) (B).
ennox-Gastaut syndrome patients who enrolled in
hese RCTs were also invited to enter an open-label
tudy (GWPCARE5; Thiele et al., 2019a). The interim
ata after 48 weeks of treatment revealed a 48-60%7
edian decrease in drop seizure frequency and a
8-57% median decrease in monthly total seizure fre-
uency relative to baseline (figure 1).
ased on the patient or caregiver Clinical Global
mpression (CGI) scale, overall improvements were
eported in patients of each trial: 58% patients (com-
ared to 34% in the placebo group) in the study of
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hiele et al. (2018), 57% and 66% in the 20 mg/kg/day
nd 10 mg/kg/day group, respectively (compared to
4% in the placebo group) in the study of Devinsky
t al. (2018b), and 88% at 24 weeks (also similar at 38
nd 48 weeks) in the open-label study of Thiele et al.
2019a).
ravet syndrome
or Dravet syndrome, two trials involved an initial
ouble-blind placebo-controlled trial (n=120) (GWP-
ARE1B; Devinsky et al., 2017) and a later open-label
xtension programme (GWPCARE5; Devinsky et al.,
019). An additional trial has also recently been com-
leted (GWPCARE2; Miller et al., 2019). For the former,
imilar to the Lennox-Gastaut syndrome trials, patients
ere administered 20 mg/kg/day CBD over a 14-week
reatment period, and data were compared relative to
four-week baseline period. For the open-label exten-
ion programme, a subset of these patients together
ith participants from the recently completed GWP-
ARE2 trial were enlisted (n=189) and followed over 48
eeks. For the controlled trial, during the treatment
eriod, the median percent reduction of convulsive
eizures and total seizures was 39% and 29% in the
BD arm relative to 13% and 9% in the placebo
rm, respectively. The difference in median percent
eduction in non-convulsive seizures was not signif-
cant. During the open-label extension programme,
he median percent reduction of total seizures con-
inued at between 39% and 51% over a 48-week period
figure 2).
s part of the expanded access programme men-
ioned above, the long-term effect of add-on CBD at
p to 25-50 mg/kg/day over a period of 144 weeks
as reported forDravet syndromeandLennox-Gastaut
yndrome patients (Laux et al., 2019). Monthly major
otor seizureswere reducedby50%and total seizures
y 44%, with consistent reductions in both seizure
ypes across the treatment period, thus supporting
BD as a long-term treatment option.
ased on the patient or caregiver CGI scale, over-
ll improvements were reported for both trials: 62%
atients (compared to 34% in the placebo arm) in the
tudy of Devinsky et al. (2017), and 85% at 48 weeks in
he open-label study of Devinsky et al. (2019).
uberous sclerosis complex
clinical trial (GWPCARE6) for Epidiolex as add-n treatment in patients with tuberous sclerosis
omplex (TSC) was completed earlier this year and
as also revealed promising results (Thiele et al.,
019b). Patients were randomised into two groups
ith Epidiolex (25 or 50 mg/kg/day) or placebo. Of
he 201 patients who completed the study, total
eizure frequency was decreased by 48% (p=0.0013),
d
C
O
a
f
t
Digure 2. Median percent reduction of Dravet syndrome total
eizures and convulsive seizures based on the controlled trial of
evinsky et al. (2017) and the open-label extension programme
f Devinsky et al. (2019).
8% (p=0.0018) and 27%, and 50% seizure reduction
n 36% (p=0.0692), 40% (p=0.0245), and 22% in the
0 mg/kg/day, 50 mg/kg/day and placebo groups,
espectively. An overall improvement, based on the
aregiver CGI scale, was reported for 69% (p=0.0074),
2% (p=0.580) and 40% in the three groups, respec-
ively. In conclusion, Epidiolex significantly reduced
eizures in TSC patients. The therapeutic effect of the
ower 25mg/kg/day concentrationwas similar to that of
he higher 50 mg/kg/day dose, and since the latter was
ssociatedwithmoreAEs (seebelow), the25mg/kg/day
ose would therefore be indicated for these
atients.
ther syndromes
ased on an open-label trial for compassionate use,
BD was tested as a treatment for CDKL5 deficiency
isorder and Aicardi, Doose, and Dup15q syndromes
ver a 12-week period (n=55) (Devinsky et al., 2018c).
he mean decrease in convulsive seizure frequency
as 51.4% (n=35). Studies are underway to evaluate
BD efficacy for a broader range of epilepsy syn-
romes and more than 20 trials are currently listed atEpileptic Disord, Vol. 22, No. 1, February 2020
linicalTrials.gov.
verall, evidence from open-label studies suggests
favourable effect of CBD as an add-on treatment
or a number of severe epileptic conditions and
he controlled trials for Lennox-Gastaut syndrome,
ravet syndrome and TSC provide a clearer picture
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if the positive effect of CBD, in some cases even
orrelating with seizure freedom. A general positive
rend for quality of life (particularly in Lennox-Gastaut
yndrome patients), sleep behaviour (particularly in
ravet syndrome patients) and adaptive behaviour
as reported. There were also particular improve-
ents in the socialisation domain and communication
omain for Dravet syndrome and Lennox-Gastaut
yndrome patients, respectively. In the prospective,
pen-label clinical study by Rosenberg et al. (2017b),
n which caregiver-reported quality of life (n=48)
as evaluated for a subset of patients treated with
BD for 12 weeks, improvements (in energy/fatigue,
emory, control/helplessness, other cognitive func-
ions, social interactions, behaviour and global QOL)
ere not related to changes in seizure frequency or
Es, suggesting that CBD may have beneficial effects
n patient QOL, distinct from anti-seizure effects,
owever, this should be confirmed in controlled
tudies.
dverse effects
n contrast to artisanal CBD-related products, the AEs
ssociated with purified CBD have been more clearly
emonstrated based on the open-label trials and,
articularly, the randomised, double-blind placebo-
ontrolled trials (Anciones and Gil-Nagel, 2020).
ased on the collective data from the controlled tri-
ls, AEs were frequently reported (86% in CBD groups
nd 76% inplacebogroups), however, the vastmajority
f AEs were mild and moderate. These included som-
olence, decreased appetite, pyrexia and diarrhoea,
ollowed by other less frequent AEs such as vomit-
ng, fatigue and upper respiratory infections (table 3).
ost AEs appeared within the first two weeks of
reatment. Serious AEs were far less common (affect-
ng 19% of CBD groups and 9% of placebo groups).
hese included, in particular, somnolence, pyrexia,
onvulsion, rash, lethargy and elevated transaminases
>three times the normal upper limit). The latter
ccurred in 16% patients in the CBD groups and 1%
n the placebo groups. Moreover, in >79-100% of the
ases with elevated transaminases, patients were con-
omitantly taking valproate.
o seizure worsening, suicidal ideation or deaths
elated to the treatment were reported. It should be
mphasised, however, given the novelty of Epidiolex,pileptic Disord, Vol. 22, No. 1, February 2020
hat long-term AEs are currently unknown.
n the recent TSC trial with the higher dose of
0 mg/kg/day CBD (Thiele et al., 2019b), AEs were
ommon but similarly overall reported as mild and
oderate (93%, 100% and 95% in the 25 mg/kg/day;
0 mg/kg/day and placebo groups, respectively).
he most common AEs were diarrhoea, decreased
h
o
p
d
c
i
oEpilepsy and cannabidiol
ppetite, and somnolence, and treatment discontin-
ation due to AEs occurred in 11%, 14% and 3%,
espectively. Elevated liver enzymes were reported in
2% (n=9) and 25% (n=18) in the 25 mg/kg/day and
0 mg/kg/day, respectively (of those, 81% were also
aking valproate).
ecommendations for use
BD is administered orally as an oil solution. In open-
abel studies, doses mostly up to 25 mg/kg/day were
sed, and in the controlled studies, higher doses up
o 50 mg/kg/day were used. The studies on Lennox-
astaut syndrome, however, show that a significant
roportion of children respond to doses of as little as
0 mg/kg/day. Therefore a “start slow” and “increase
n a case-by-case basis” strategy is recommended. A
tarting dose of 5 mg/kg/day, divided in two doses,
ould appear to be adequate. This dose should be
ncreased to 10 mg/kg/day after two weeks of treat-
ent. Thereafter, the individual’s response should
e carefully observed. The required observation time
trictly depends on baseline seizure frequency before
he administration of CBD. If the drug is well toler-
ted but not sufficiently effective, the dose should be
lowly increased in increments of 5 mg/kg/day, as long
s it is tolerated, up to a maximum of 20-25 mg/kg/day
table 4).
s mentioned above, special care should be taken
f both CBD and clobazam are administered, since
he addition of CBD may lead to an increase
up to five-fold) in its less potent metabolite, N-
esmethylclobazam.A toxic benzodiazepine levelmay
anifest as fatigue, somnolence, ataxia, a decrease
n cognitive function or behavioural changes. Clini-
ally, these aredifficult todistinguish from thepossible
Es of CBD itself and monitoring of clobazam/N-
esmethylclobazam levels is therefore recommended.
aseline therapeutic drug monitoring should be
erformed before administration of CBD and subse-
uently after each increase. If a significant increase
n benzodiazepine level is observed, the dose of
lobazam should be reduced (and then checked),
ccording to an estimate based on linear kinetics.
ike CBD, however, stiripentol inhibits the same P450
ubtype 2C19 (CYP2C19), and an increase in benzodi-
zepine level may not, therefore, occur if the patient
s already on stiripentol (Devinsky et al., 2018b). It is9
ighly recommended to follow serum concentrations
f all drugs when initiating CBD as a basis for appro-
riate dosage adjustment. This includes psychotropic
rugs (mood stabilisers, antidepressants, and antipsy-
hotics) in order to reveal possible pharmacokinetic
nteractions or reasons for poor clinical effects or
bserved AEs.
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Table 3. Adverse events based on randomised, double-blind, placebo-controlled trials
(the most frequent adverse events are highlighted in grey).
Dravet syndrome Lennox-Gastaut syndrome
Devinsky et al.,
2017
Devinsky et al.,
2018a
Devinsky et al.,
2018b
Thiele et al.,
2018
CBD
(n=61)
Placebo
(n=59)
CBD
(n=27)
Placebo
(n=7)
CBD
(n=149)
Placebo
(n=76)
CBD
(n=86)
Placebo
(n=85)
[CBD] mg/kg/day 20 - 5, 10 or 20- 10 or 20 - 20 -
Reported AEs (%)
Reported serious AEs (n)
Withdrawn (n)
93
10
8
75
3
1
74
5
2
86
1
-
89
26
7
72
13
1
86
20
12
69
4
1
Somnolence (n)*a 22 6 5 1 39 4 25 15
Decreased appetite (n) 17 3 5 0 32 6 19 3
Pyrexia (n)* 9 5 6 0 16 12 12 8
Diarrhoea (n) 19 6 19 6 27 10
Elevated transaminases (n)*b 12 1 6 - 14 0 20 1
Vomiting (n) 9 3 3 0 10 9 15 18
Fatigue (n) 12 2 1 2
Upper respiratory infections (n) 7 5 21 11
Pharyngitis (n) 3 2 12 5
Convulsion (n)* 7 3 1 2
Sedation (n) 4 0
Ataxia (n) 3 0
Rash (n)* 2 0
Non-specified pneumonia (n) 2 0
Lethargy (n)* 8 3
Status epilepticus (n) 3 3
*Serious adverse events reported in≤2 patients per RCT. aMajority of
valproate (transaminases were elevated >3 times the upper normal li
Table 4. Guide to CBD dosing.
1 Start low (5 mg/kg/day), increase to 10 mg/kg/day after
two weeks
2 Review clinical response and adverse effects at
10 mg/kg/day
3 Remain on this dose if effective, otherwise increase
dose in steps of 5 mg/kg/day if CBD is well tolerated
4 Stop at 20-25 mg/kg/day, and withdraw CBD if
ineffective
P
f
b
t
F
m
j
e
e
t
e
p
a11 3 1 1
patients were also taking clobazam. b>79% patients were taking
mit).
harmacogenetic testing for CYP2C19 could be per-
ormed if a poor metabolizer genotype is suspected
ased on unexpectedly high levels of CBD relative to
he dose.
inally, biochemical markers of toxicity should be
easured, particularly regarding liver enzymes in con-Epileptic Disord, Vol. 22, No. 1, February 2020
unction with valproate (Gaston et al., 2017; Devinsky
t al., 2018a). In the controlled studies, increased liver
nzymes led to withdrawal of CBD if levels were more
han three times the upper normal limit in the pres-
nce of any symptoms (fever, rash, nausea, abdominal
ain or increasedbilirubin) or eight times higher in the
bsence of such symptoms. In rare cases, an increase
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tn enzymeswas observedwith 20mg/kg/dayCBDwith-
ut concomitant use of valproate, but not with lower
oses of CBD. Overall, the increase in liver enzymes
as reversible in about half the cases, without taking
ny action; in the remaining cases, CBD was with-
rawn, leading to normalisation of levels (Devinsky et
l., 2018b). A mild increase in enzyme levels may be
bserved over a few weeks before taking any action,
owever, as levels become too high, CBD or valproate
hould be withdrawn or reduced, according to the
enefit of each.
onclusions
iven the range of, and easy access to CBD-enriched
ils on the market, alongside the fallacious percep-
ion that “natural” products may be safer with fewer
Es than conventional AEDs, it is clear to see why
uch products are popular. However, analytical con-
rols for CBD-enriched products are not mandatory,
eaving consumers with no legal protection or guar-
ntees about the composition and quality of the
roduct they are acquiring. Currently, CBD-enriched
roducts are not subject to any obligatory testing or
asic regulatory framework to determine the indi-
ation area, daily dosage, route of administration,
aximum recommended daily dose, packaging, shelf
ife or stability. The content of these products is there-
ore highly variable and although components other
han CBD are present which may even be beneficial,
here is currently no way this can be ascertained or
ontrolled.
n contrast, purified CBD, in the form of Epid-
olex/Epidyolex, is a standardised pharmaceutical
reparation that is subject to minimal variability.
ased on controlled trials, Epidiolex appears to be an
ffective treatmentoption forpatientswithDravet syn-
rome, Lennox-Gastaut syndrome and TSC and has a
elatively good safety profile, although it should be
mphasised that, at least from the controlled trials,
BD does not outperform other drugs and will by no
eans represent a silver bullet for everyone. It does,
owever, add to the arsenal of available add-on drugs
gainst these severe forms of epilepsy, in some cases
ffering substantial benefits.
iven the range of different seizure types associ-
tedwithDravet syndrome, Lennox-Gastaut syndrome
nd TSC, CBD would appear to have a favourablepileptic Disord, Vol. 22, No. 1, February 2020
ffect on a large spectrum of convulsive (consis-
ent with preclinical data), rather than non-convulsive
eizures (Devinsky et al., 2017), namely clonic,
yoclonic, myoclonic-astatic, and generalised tonic-
lonic seizures. It should be noted, however, that
he effect of CBD on specific types of seizures
as not described in detail in the controlledEpilepsy and cannabidiol
rials and further studies will therefore be required
o address this. Other forms of intractable epilepsy
ases have been investigated in open-label trials
CDKL5 deficiency disorder and Aicardi, Dup15q and
oose syndromes; Devinsky et al., [2018c]), and
ore than 20 trials are currently listed at ClinicalTri-
ls.gov (including Rett syndrome and other forms of
ntractable epilepsy). Although these syndromes col-
ectively represent a small fraction of the epilepsy
opulation, clinical trials in the future may lead
o CBD or indeed other cannabinoids being indi-
ated more broadly across the spectrum of epilepsy
yndromes. 
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TEST YOURSELF
EDUCATION
(1) What are the groups of known physiologically active components of cannabis?
(2) What is the maximum ratio of CBD to THC in artisanal products advertised with CBD content?
(3) What is the effect of THC on seizures?
(4) Epidiolex has been shown to be efficacious for which epileptic syndromes based on RCTs?
(5) Based on RCTs, what are the main adverse effects of Epidiolex?
(6) Which adverse effect is associated with clobazam in combination with Epidiolex?4 Epileptic Disord, Vol. 22, No. 1, February 2020
(7) Which adverse effect is associated with valproate in combination with Epidiolex?
Note: Reading the manuscript provides an answer to all questions. Correct answers may be accessed on the
website, www.epilepticdisorders.com, under the section “The EpiCentre”.
